Rare or Common? Germline variants likely impacting patient therapy response

Schematic illustrations depicting the mapping of frameshift and stop creating human germline variants affecting the extracellular domains of human membrane proteins targeted by FDA-approved monoclonal antibodies. The presence of such germline variants may compromise the therapeutic efficacy and the therapeutic outcomes of clinically approved therapeutic agent.